The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for avutometinib to be used in combination with defactinib for the treatment of adults with ...
Plixorafenib is under clinical development by Fore Biotherapeutics and currently in Phase II for Low-Grade Glioma. According to GlobalData, Phase II drugs for Low-Grade Glioma have a 64% phase ...